Helicobacter pylori infection Medical Services in China

Helicobacter pylori (H. pylori) infection is a chronic bacterial colonization of the gastric mucosa, primarily affecting the stomach and duodenum. First identified in 1982 by Barry Marshall and Robin Warren, this gram-negative, microaerophilic, spiral-shaped bacterium survives the acidic gastric environment by producing urease—an enzyme that hydrolyzes urea into ammonia and carbon dioxide, thereby neutralizing local acidity. Pathogenesis involves bacterial adhesion to gastric epithelial cells via adhesins (e.g., BabA, SabA), induction of inflammation through virulence factors (notably CagA and VacA), disruption of tight junctions, oxidative stress, and progressive mucosal injury. Over time, persistent infection can lead to chronic gastritis, peptic ulcer disease (PUD), gastric mucosa-associated lymphoid tissue (MALT) lymphoma, and is classified by the WHO as a Group I carcinogen due to its strong causal association with gastric adenocarcinoma—accounting for approximately 90% of non-cardia gastric cancers. Epidemiologically, H. pylori infects nearly half the global population, with prevalence exceeding 70% in low- and middle-income countries and ranging from 20–40% in high-income nations. Infection is typically acquired in childhood, often through oral–oral or fecal–oral routes, and clusters within families and crowded living conditions. Key risk factors include poor sanitation, inadequate clean water access, lower socioeconomic status, overcrowded housing, and limited education. While many infected individuals remain asymptomatic, symptomatic patients commonly report epigastric pain, early satiety, bloating, nausea, belching, and halitosis; severe complications such as gastrointestinal bleeding, perforation, or obstruction may arise from untreated ulcers. Importantly, H. pylori infection significantly impairs quality of life—not only through physical discomfort and dietary restrictions but also via anxiety related to cancer risk, recurrent symptoms, treatment side effects (e.g., antibiotic-associated diarrhea, taste disturbances), and work absenteeism. Psychological burden—including health-related worry and reduced social engagement—is increasingly recognized in longitudinal studies. Early diagnosis—via non-invasive tests (urea breath test, stool antigen assay, serology) or invasive methods (rapid urease test, histology, culture during endoscopy)—is critical for timely eradication and prevention of long-term sequelae. Given rising global antimicrobial resistance—especially to clarithromycin, metronidazole, and levofloxacin—treatment must be tailored regionally and guided by susceptibility testing where available.

Helicobacter pylori (H. pylori) infection is a chronic bacterial colonization of the gastric mucosa, primarily acquired during childhood and persisting for decades if untreated. The primary cause is direct person-to-person transmission, most commonly via oral–oral or fecal–oral routes. Oral–oral transmission may occur through saliva exchange—such as sharing utensils, pre-chewing food for infants, or kissing—particularly in crowded or low-resource settings. Fecal–oral transmission is facilitated by ingestion of contaminated water or food, especially where sanitation infrastructure is inadequate. H. pylori does not survive well outside the human stomach; thus, environmental reservoirs (e.g., soil, animals) are not considered epidemiologically significant. Person-to-person spread within families is well documented, with higher concordance rates among siblings and between parents and children, underscoring the importance of household clustering.

Triggers for symptomatic disease or complications are multifactorial and often involve disruption of the host–pathogen equilibrium. Gastric acid suppression—whether from proton pump inhibitors (PPIs), H2-receptor antagonists, or physiological hypochlorhydria—may transiently alter gastric ecology and promote bacterial proliferation or migration into the gastric corpus, potentially exacerbating inflammation. Acute stressors—including severe illness, major surgery, or burns—can impair mucosal defense mechanisms and unmask latent infection or precipitate erosive gastropathy. Concurrent use of nonsteroidal anti-inflammatory drugs (NSAIDs) or aspirin synergistically increases the risk of ulcer formation and bleeding in infected individuals by compromising mucosal prostaglandin synthesis and microvascular integrity. Smoking and excessive alcohol consumption act as co-triggers by inducing oxidative stress, reducing mucosal blood flow, and impairing epithelial restitution.

Established risk factors include socioeconomic determinants: low income, overcrowded living conditions, poor sanitation, and limited access to clean water significantly increase acquisition risk, particularly before age 10. Geographic disparities are pronounced—prevalence exceeds 70–80% in many low- and middle-income countries (e.g., parts of Latin America, Africa, and Asia), compared with 20–50% in North America and Western Europe. Immigration status is an independent risk factor, reflecting both origin-region prevalence and post-migration socioeconomic barriers to care. Other clinical risk factors include institutionalization (e.g., long-term care facilities), prior gastric surgery (e.g., partial gastrectomy), and immunocompromised states such as HIV/AIDS or prolonged corticosteroid use—though immunosuppression does not consistently increase acquisition, it may alter disease phenotype and diagnostic sensitivity.

Genetic factors influence susceptibility, severity, and clinical outcomes—not acquisition per se. Polymorphisms in proinflammatory cytokine genes, notably IL-1β (IL1B-31C/T, -511T/C), IL-10 (IL10-592C/A, -819C/T), and TNF-α (TNFA-308G/A), modulate gastric inflammatory responses. Carriers of high-producer IL-1β alleles exhibit enhanced acid suppression, greater atrophic gastritis risk, and elevated gastric adenocarcinoma odds (OR 2–10). Similarly, IL-10 promoter variants associated with reduced anti-inflammatory signaling correlate with more severe histologic injury. Host glycosylation patterns—especially Lewis antigen expression (FUT2 secretor status)—affect bacterial adhesion; non-secretors demonstrate reduced binding of H. pylori BabA adhesin and lower infection persistence. Genome-wide association studies have identified additional loci near PSCA and PRKAA1, implicating epithelial barrier function and cellular metabolism in disease modulation.

Environmental factors extend beyond hygiene and sanitation to include dietary habits and microbial exposures. Diets high in salted, smoked, or nitrate-preserved foods promote gastric atrophy and carcinogenesis in infected hosts, while diets rich in antioxidants (vitamin C, E, selenium) and fresh produce may attenuate oxidative DNA damage. Early-life exposure to diverse commensal microbiota—via vaginal delivery, breastfeeding, and rural upbringing—may confer protective immune education, whereas antibiotic overuse in infancy disrupts microbiome development and potentially increases susceptibility. Air pollution (e.g., PM2.5) and chronic exposure to indoor biomass smoke have been associated with increased gastric inflammation and H. pylori-related pathology in epidemiologic studies, though mechanistic links remain under investigation. Importantly, no credible evidence supports zoonotic transmission from pets or livestock; human-to-human spread remains the sole validated route of acquisition.

Helicobacter pylori (H. pylori) infection is a chronic bacterial colonization of the gastric mucosa, affecting approximately half the global population. While most infected individuals remain asymptomatic, a subset develops clinically significant upper gastrointestinal pathology, primarily gastritis, peptic ulcer disease (PUD), gastric mucosa-associated lymphoid tissue (MALT) lymphoma, and, in rare cases, gastric adenocarcinoma. Symptoms vary widely depending on host immune response, bacterial virulence factors (e.g., CagA, VacA), duration of infection, and coexisting conditions such as NSAID use or smoking. Early symptoms—often subtle and nonspecific—may manifest within weeks to months after acquisition and include intermittent epigastric discomfort, mild postprandial fullness, occasional nausea, and reduced appetite. These early manifestations are frequently mistaken for functional dyspepsia or dietary intolerance and rarely prompt medical evaluation. Notably, early infection may be entirely silent; seroconversion typically occurs 3–12 weeks post-exposure, yet symptom onset—if it occurs—is highly variable and not reliably time-locked to serological markers.

Typical symptoms reflect established chronic active gastritis or ulceration. The hallmark is recurrent, burning or gnawing epigastric pain, often occurring 1–3 hours after meals or during fasting (nocturnal pain), and characteristically relieved by antacids or food ingestion—though this relief may be transient and inconsistent. Unlike gastroesophageal reflux disease (GERD), the pain is rarely retrosternal or associated with heartburn or regurgitation. Patients commonly report persistent dyspepsia defined by ≥1 of the following: postprandial bloating, early satiety, epigastric burning, or nausea—without evidence of structural disease on initial imaging. In duodenal ulcer cases, pain may radiate to the back or right hypochondrium; in gastric ulcers, pain is more likely to worsen with eating. Hematemesis or melena may occur even in the absence of overt ulceration due to H. pylori-induced mucosal erosion and microvascular injury.

Accompanying symptoms reflect systemic or extragastric effects and comorbid inflammatory states. Chronic low-grade inflammation can lead to iron deficiency anemia (due to occult blood loss and impaired iron absorption secondary to hypochlorhydria and hepcidin upregulation), vitamin B12 deficiency (from atrophic gastritis and intrinsic factor impairment), and unexplained thrombocytopenia (immune-mediated, as seen in H. pylori–associated ITP). Some patients report halitosis (attributed to urease-mediated ammonia production), chronic bad taste (dysgeusia), or recurrent aphthous stomatitis—though causal links remain debated. Fatigue, low-grade fever, and weight loss may accompany advanced atrophic gastritis or MALT lymphoma but are uncommon in uncomplicated infection. Importantly, H. pylori has been epidemiologically associated with idiopathic urticaria, rosacea, and chronic spontaneous urticaria, though mechanistic evidence is limited and these are not diagnostic indicators.

Complications arise from progressive mucosal damage and immune dysregulation. Peptic ulcer complications include hemorrhage (most common), perforation (sudden, severe, board-like abdominal rigidity), and gastric outlet obstruction (persistent vomiting, succussion splash, weight loss). Gastric atrophy and intestinal metaplasia—precancerous lesions—develop over decades in a subset of patients, particularly those with corpus-predominant gastritis, increasing lifetime risk of gastric adenocarcinoma (relative risk ~3–6×). H. pylori is classified as a Group I carcinogen by the WHO/IARC. Gastric MALT lymphoma, an indolent B-cell lymphoma, is strongly associated with H. pylori (present in >90% of cases); eradication therapy alone induces complete remission in ~75% of localized stage I disease. Rarely, infection contributes to refractory iron-deficiency anemia, autoimmune gastritis exacerbation, or idiopathic thrombocytopenic purpura (ITP) relapse.

Diagnosis requires confirmation of active infection—not merely past exposure. Non-invasive methods include the urea breath test (UBT), which detects labeled CO2 after oral ingestion of 13C- or 14C-urea (sensitivity/specificity >95%); stool antigen test (SAT) using monoclonal antibodies (sensitivity 94%, specificity 95%); and serology (IgG antibodies), which indicates exposure but cannot distinguish active from past infection and remains positive for months after eradication—thus unsuitable for post-treatment confirmation. Invasive diagnosis relies on upper endoscopy with biopsy: rapid urease test (RUT) on gastric antral and corpus specimens (sensitivity ~90–95%, dependent on bacterial load and PPI use); histopathology (gold standard for assessing gastritis pattern, atrophy, metaplasia, and malignancy); and culture (low yield, <70%, but essential for antibiotic susceptibility testing in treatment failure). Molecular methods (PCR) offer high sensitivity and resistance profiling but are not routinely available. Testing should be performed off PPIs for ≥2 weeks and antibiotics/bismuth for ≥4 weeks to avoid false negatives.

Differential diagnosis is critical, as symptoms overlap extensively with other upper GI disorders. Functional dyspepsia shares identical symptom profiles (Rome IV criteria) but lacks organic findings and H. pylori infection; however, H. pylori–positive functional dyspepsia represents a distinct clinical entity requiring eradication. GERD presents with retrosternal burning, regurgitation, and acid brash—rarely isolated epigastric pain—and responds poorly to H. pylori eradication. Gastric or duodenal malignancy must be excluded in patients >55 years, with alarm features (weight loss, anemia, dysphagia, persistent vomiting, palpable mass, or family history), as H. pylori increases cancer risk but does not cause identical acute symptoms. NSAID-induced gastropathy mimics ulcer symptoms but lacks bacterial etiology and shows different histologic patterns (focal erosions vs. diffuse chronic active gastritis). Autoimmune gastritis presents with pernicious anemia, achlorhydria, and anti-parietal cell antibodies—typically without active H. pylori, though coexistence is possible. Other considerations include Zollinger-Ellison syndrome (hypergastrinemia, multiple ulcers, diarrhea), eosinophilic gastritis (peripheral eosinophilia, biopsy-proven infiltration), and celiac disease (diarrhea, steatorrhea, dermatitis herpetiformis). Accurate diagnosis hinges on integrating clinical presentation, risk stratification, appropriate testing, and endoscopic evaluation when indicated.

Helicobacter pylori (H. pylori) infection is a common bacterial colonization of the gastric mucosa, implicated in chronic gastritis, peptic ulcer disease, gastric mucosa-associated lymphoid tissue (MALT) lymphoma, and gastric adenocarcinoma. Management requires eradication therapy to prevent complications and recurrence. Treatment strategies are stratified into conservative (pharmacologic) approaches, surgical interventions (rarely indicated), and comprehensive recovery support. In China, national guidelines—such as those issued by the Chinese Society of Gastroenterology (CSG) and the Chinese Medical Association—are rigorously evidence-based, incorporating regional antibiotic resistance patterns and real-world clinical outcomes.

Conservative treatment remains the cornerstone of H. pylori management. First-line regimens emphasize high-eradication efficacy (>90%), tolerability, and adherence. The current standard in China is bismuth-containing quadruple therapy (BQT), recommended for 10–14 days: a proton pump inhibitor (PPI) (e.g., esomeprazole 20 mg or rabeprazole 10 mg twice daily), bismuth subcitrate potassium 220 mg twice daily, tetracycline 500 mg four times daily, and metronidazole 400 mg three or four times daily. This regimen achieves >92% eradication in regions with high clarithromycin resistance (>15%), which is prevalent across much of China. Alternative first-line options include concomitant therapy (PPI + amoxicillin + clarithromycin + metronidazole for 10–14 days) or hybrid therapy (sequential initiation with amoxicillin/PPI for 5 days, followed by PPI + amoxicillin + clarithromycin + metronidazole for 5 days), though BQT is preferred due to superior efficacy and lower resistance-driven failure. Second-line therapy is guided by antimicrobial susceptibility testing when available; otherwise, levofloxacin-based triple therapy (PPI + amoxicillin + levofloxacin) or rifabutin-based regimens may be used after failure of initial BQT. All regimens require strict adherence—missed doses significantly reduce eradication rates. Pharmacokinetic considerations are critical: PPIs must be dosed twice daily at optimal pH to maximize antibiotic stability (e.g., amoxicillin degrades rapidly in acidic environments), and bismuth enhances mucosal barrier function while exerting direct antibacterial effects.

Surgical treatment is not indicated for uncomplicated H. pylori infection. Surgery plays a strictly limited role and is reserved for rare, severe complications unresponsive to medical therapy. These include refractory bleeding ulcers with hemodynamic instability despite endoscopic intervention and pharmacologic control; perforated peptic ulcers requiring emergency laparoscopic or open repair; or gastric outlet obstruction secondary to chronic scarring and stenosis. In cases of H. pylori–associated early gastric cancer or high-grade dysplasia, endoscopic submucosal dissection (ESD) or gastrectomy may be performed—but these address neoplastic transformation, not the infection itself. Importantly, surgical resection does not obviate the need for postoperative eradication therapy, as residual gastric mucosa remains susceptible to reinfection or metachronous lesions. Therefore, surgery is adjunctive—not curative—for H. pylori, and all patients undergoing gastric resection should receive confirmatory postoperative H. pylori testing and targeted eradication if positive.

Treatment advantages in China stem from integrated, guideline-driven care delivery. First, nationwide surveillance networks (e.g., the China Antimicrobial Resistance Surveillance System for H. pylori) continuously monitor regional resistance trends—particularly clarithromycin, metronidazole, and levofloxacin—enabling dynamic regimen selection. Second, China’s robust primary-to-tertiary healthcare referral system ensures timely access to gastroenterology specialists and standardized breath tests (13C-urea breath test), stool antigen assays, and endoscopic biopsies with rapid urease testing and histopathology. Third, cost-effective generic formulations of bismuth compounds, tetracyclines, and PPIs are widely subsidized under the National Reimbursement Drug List, improving adherence in low-income populations. Fourth, digital health platforms (e.g., WeDoctor, Ping An Good Doctor) facilitate medication reminders, symptom diaries, and teleconsultations—proven to improve 14-day adherence by 27% in multicenter trials. Finally, China’s large-scale prospective registries (e.g., the China H. pylori Eradication Registry) generate real-world effectiveness data that directly inform iterative guideline updates—demonstrating sustained >90% eradication with optimized BQT protocols across diverse geographic and socioeconomic cohorts.

Recovery advice emphasizes both physiological healing and long-term prevention. Patients must complete the full antibiotic course—even if symptoms resolve early—to prevent selection of resistant strains. Symptom relief (e.g., epigastric pain, bloating) typically begins within 3–5 days but does not indicate eradication. Confirmatory testing is mandatory 4 weeks after therapy completion and ≥2 weeks after discontinuing PPIs (to avoid false-negative results); the 13C-urea breath test is preferred for its high sensitivity (95%) and specificity (98%). Lifestyle modifications support mucosal recovery: avoidance of NSAIDs, aspirin, alcohol, and tobacco; consumption of small, frequent meals; and restriction of highly spiced, acidic, or fried foods during active treatment. Probiotic supplementation (e.g., Lactobacillus reuteri DSM17648 or Saccharomyces boulardii CNCM I-745) may reduce antibiotic-associated diarrhea and improve eradication rates by 5–10%, though strain-specific evidence is required. Long-term follow-up includes annual symptom assessment and repeat testing only if new ulcer symptoms, unexplained iron-deficiency anemia, or alarm features (e.g., weight loss, vomiting, hematemesis) emerge. Family screening is advised in high-prevalence households, given fecal-oral and oral-oral transmission risks. Finally, dietary patterns rich in cruciferous vegetables (sulforaphane), green tea polyphenols, and fermented foods may confer adjunctive anti-H. pylori activity, though they are not substitutes for pharmacotherapy. With structured, guideline-adherent care, >95% of patients achieve durable eradication, significantly reducing lifetime risk of gastric malignancy and recurrent ulceration.